1-20 of 279
Poster Presentations - Proffered Abstracts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P171: Ligand-displaying-exosomes using RNA nanotechnology for targeted delivery of multispecific drugs for liver cancer regression

Xin Li, Satheesh Ellipilli, Hongzhi Wang, Wen-Jui Lee, Yuan Soon Ho, Peixuan Guo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P171.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P171
Published: 01 December 2021
View article
Journal Articles

Abstract P170: SpliceCore® a platform for identifying aberrant alternative splicing in triple negative breast cancer for novel therapeutic development

Miguel A. Manzanares, Dhingra Priyanka, Kendall Anderson, Vanessa Frederick, Adam Geier, Alyssa Casill, Martin Akerman, Gayatri Arun
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P170.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P170
Published: 01 December 2021
View article
Journal Articles

Abstract P169: Dynamic cell-level modeling of antibody binding and internalization for radiosensitivity assessements in alpha-emitter radiopharmaceutical therapy

Remco Bastiaannet, Ioanna Liatsou, Robert Hobbs, George Sgouros
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P169.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P169
Published: 01 December 2021
View article
Journal Articles

Abstract P168: Pretargeted radioimmunotherapy using 225Ac for intraperitoneal Her2-expressing epithelial ovarian carcinoma xenografts

Sebastian K. Chung, Christopher S. Chandler, Daniela Burnes Vargas, Shin H. Seo, Michael R. McDevitt, Darren Veach, Blesida Punzalan, Xu Hong, Hong-fen Guo, Garrett M. Nash, Andrea Cercek, Nai-Kong V. Cheung, Steven M. Larson, Sarah M. Cheal
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P168.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P168
Published: 01 December 2021
View article
Journal Articles

Abstract P106: Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy

Peter Keller, Irina Mazo, Yun Gao, Vijayapal Reddy, Francisco Caballero, Sam Kazer, Dannah Miller, Roberto Gianani, James E. Marvin, Bret Stephens, Gregory L. Beatty, Ulrich H. von Andrian, Thorsten R. Mempel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P106.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P106
Published: 01 December 2021
View article
Journal Articles

Abstract P105: Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures

Steve Sazinsky, Ani Nguyen, Mohammad Zafari, Ryan Phennicie, Joe Wahle, Veronica Komoroski, Kathryn Rooney, Craig Mizzoni, Boris Klebanov, Jessica Ritter, Denise Manfra, Igor Feldman, Tatiana Novobrantseva
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P105.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P105
Published: 01 December 2021
View article
Journal Articles

Abstract P048: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)

D. Ross Camidge, Jonathan Pachter, Andrew Koustenis, Gloria Patrick, David R. Spigel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P048.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P048
Published: 01 December 2021
View article
Journal Articles

Abstract P243: The IRAK4 inhibitor CA-4948 demonstrates antitumor activity in a preclinical model of CNS lymphoma

Christina A. von Roemeling, Bently P. Doonan, Lan Hoang-Minh, Han W. Tun, Elizabeth Martinez, Raul Soikes, Reinhard von Roemeling, Duane A. Mitchell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P243.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P243
Published: 01 December 2021
View article
Journal Articles

Abstract P242: Preclinical efficacy landscape of the pan-CLK/DYRK inhibitor Cirtuvivint (SM08502)

Carine Bossard, Emily Creger, Elizabeth A. McMillan, Carsten Merkwirth, Maureen Ibanez, Deepti Bhat, Josh Stewart, Brian Eastman, Chi-Ching Mak, Vishal Deshmukh, Michael A. White
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P242.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P242
Published: 01 December 2021
View article
Journal Articles

Abstract P241: A highly potent HPK1 inhibitor augments immune cell activation and anti-tumor immunity in a syngeneic tumor mouse model

Hao Liu, Lei Wu, Song Feng, Wei Huang, Huijuan Li, Jing Lin, Yangyang Liu, Liufeng Mei, Baoqi Ren, Julie Xie, Lili Yao, Wenge Zhong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P241.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P241
Published: 01 December 2021
View article
Journal Articles

Abstract P240: Benchmarking the novel dual-MEK inhibitor, IMM-1-104, head-to-head and in combination with sotorasib (AMG-510) in the MIA PaCa-2 (KRAS-G12C) pancreatic cancer xenograft model

Peter J. King, Amy E. Axel, Kevin D. Fowler, Sarah E. Kolitz, Scott Barrett, Benjamin J. Zeskind, Brett M. Hall
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P240.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P240
Published: 01 December 2021
View article
Journal Articles

Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors

Benedito A. Carneiro, Robert Jotte, Nashat Gabrail, Omid Hamid, Funan Huang, Shalini Chaturvedi, Matthias Herpers, Lidia Mongay Soler, Barrett H. Childs, Aaron Hansen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P239.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P239
Published: 01 December 2021
View article
Journal Articles

Abstract P238: Derazantinib, an inhibitor of fibroblast growth factor receptors 1-3, synergises with paclitaxel in pre-clinical gastric tumor models

Paul M. McSheehy, Mahmoud El Shemerly, Felix Bachmann, Laurenz Kellenberger, Heidi Lane
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P238.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P238
Published: 01 December 2021
View article
Journal Articles

Abstract P237: PRT2527 is a potent and selective CDK9 inhibitor that demonstrates anti-cancer activity in preclinical models of hematological malignancies and solid tumors with MYC amplification

Yang W. Zhang, Liang Lu, Min Wang, Dave Rominger, Stefan Ruepp, Kirsten Gallagher, William Gowen-MacDonald, Chaofeng Dai, Miles Cowart, Andrew Combs, Bruce Ruggeri, Peggy Scherle, Kris Vaddi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P237.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P237
Published: 01 December 2021
View article
Journal Articles

Abstract P236: Targeting AXL/PDK1 signaling axis activates immunogenic cell death in liver cancer

Yunong Xie, Lei Zhou, Cheuk Yin Lin, Terence Lee, Jin Ding, Stephanie Ma, Man Tong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P236.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P236
Published: 01 December 2021
View article
Journal Articles

Abstract P167: Site-specific Dolasynthen ADCs demonstrate consistent exposure across a wide range of drug-to-antibody ratios

Kalli C. Catcott, Susan Clardy, Jack Sadowsky, Rebecca K. Rowntree, Naniye Malli Centibas, Ling Xu, Andy Polson, Kenneth Avocetien, Tyler Carter, Mark Nazzaro, Dokyong "DK" Kim, Thomas H. Pillow, Neelie Zacharias, Cong Wu, Jeffrey Zurita, Elizabeth Ditty, Stephen Bradley, Alex Uttard, Bingfan Du, William S. Sawyer, Doug Leipold, Gail Lewis Phillips, LiuLiang Qin, Kelly Slocum, Geoffrey Del Rosario, Ginny Li, Shang-Fan Yu, David Lee, Radha Iyengar, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P167.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P167
Published: 01 December 2021
View article
Journal Articles

Abstract P166: The rs35112940 CD33 polymorphism reduces CD33 internalization and efficacy of CD33-directed gemtuzumab ozogamicin

Mohammed O. Gbadamosi, Vivek M. Shastri, Soheil Meshinchi, Jatinder K. Lamba
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P166.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P166
Published: 01 December 2021
View article
Journal Articles

Abstract P165: MRTX1719: A first-in-class MTA-cooperative PRMT5 inhibitor that selectively elicits antitumor activity in MTAP/CDKN2A deleted cancer models

Christopher R. Smith, Lars D. Engstrom, Svitlana Kulyk, Ruth Aranda, Laura Waters, Krystal Moya, Victoria Bowcut, Allan Hebbert, David Trinh, David M. Briere, J. David Lawson, Jeff Clarine, Lisa Rahbaek, James G. Christensen, Matthew A. Marx, Peter Olson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P165.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P165
Published: 01 December 2021
View article
Journal Articles

Abstract P164: Identification of the p53 negative feedback loop as a target for enhancing selinexor activity in neuroblastoma

Rosa Nguyen, Hong Wang, Ming Sun, Dong Geun Lee, Junmin Peng, Carol J. Thiele
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P164.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P164
Published: 01 December 2021
View article
Journal Articles

Abstract P162: Phase 1 trial of selinexor in children and adolescents with recurrent/refractory solid and CNS tumors (ADVL1414): A Children’s Oncology Group Phase 1 Consortium trial

Adam L. Green, Charles G. Minard, Xiaowei Liu, Joel M. Reid, Kerice Pinkney, Stephan Voss, Marvin D. Nelson, Elizabeth Fox, Brenda J. Weigel, Julia Glade Bender
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P162.
DOI: https://doi.org/10.1158/1535-7163.TARG-21-P162
Published: 01 December 2021
View article